Evidence map›Paper›PMID 24013231›Full record

ArticleOncogene2014

Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis.

V H Cowling, S A Turner, M D Cole

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Regulation of MicroRNAs After Spinal Cord Injury in Adult Zebrafish.Journal of molecular neuroscience : MN · 2024
    Article
  8. Article
  9. The roles of NOP56 in cancer and SCA36.Pathology oncology research : POR · 2023
    Review
  10. Targeting Transcription Factors in Cancer: From "Undruggable" to "Druggable".Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  11. ABiomedicines · 2022
    Article
  12. Article
  13. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.Journal of experimental & clinical cancer research : CR · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Multi-Omics Model Applied to Cancer Genetics.International journal of molecular sciences · 2021
    Review
  18. Article
  19. [Effect of piRNA NU13 in regulating biological behaviors of human Wilms tumor cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

V H CowlingDepartment of Pharmacology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH, USA.
S A TurnerDepartment of Genetics, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH, USA.
M D Cole1] Department of Pharmacology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH, USA [2] Department of Genetics, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH, USA.
Dartmouth College · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
FUNCTION OF THE C-MYC ONCOGENER01CA055248 · NCI · PRINCETON UNIVERSITY · PI COLE, MICHAEL DAVID · 1992 to 2020
$8.6M
Molecular and Cellular Biology at DartmouthT32GM008704 · NIGMS · DARTMOUTH COLLEGE · PI COMPTON, DUANE A. · 1998 to 2018
$6.8M
Myc Oncogene Mutations and Polymorphisms in CancerR01CA080320 · NCI · PRINCETON UNIVERSITY · PI COLE, MICHAEL DAVID · 1999 to 2014
$4.6M
Medical Research Council G0700240Medical Research Council MR/K024213/1NCI NIH HHS CA055248NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA055248NCI NIH HHS R01 CA080320NIGMS NIH HHS T32 GM008704NIGMS NIH HHS T32GM008704
6 · The paper itself

Abstract

Burkitt's lymphomas (BLs) acquire consistent point mutations in a conserved domain of Myc, Myc Box I. We report that the enhanced transforming activity of BL-associated Myc mutants can be uncoupled from loss of phosphorylation and increased protein stability. Furthermore, two different BL-associated Myc mutations induced similar gene expression profiles independently of T58 phosphorylation, and these profiles are dramatically different from MycWT. Nol5a/Nop56, which is required for ribosomal RNA methylation, was identified as a gene hyperactivated by the BL-associated Myc mutants. We show that Nol5a is necessary for Myc-induced cell transformation, enhances MycWT-induced cell transformation and increases the size of MycWT-induced tumors. Thus, Nol5a expands the link between Myc-induced regulation of nucleolar target genes, which are rate limiting for cell transformation and tumor growth.

Indexed as

MutationAnimalsBurkitt LymphomaCarcinogenesisCell LineCell ProliferationCell Transformation, NeoplasticFemaleGene Expression ProfilingHistonesHumansMiceNuclear ProteinsPromoter Regions, GeneticProto-Oncogene Proteins c-mycRatsHistonesNOP56 protein, ratNuclear ProteinsProto-Oncogene Proteins c-myc

Identifiers

PMID24013231
PMCPMC5003617
OpenAlexW1974949642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.